Currently, the company is applying its Lecinoxoid technology to anti-inflammatory indications, including psoriasis and ulcerative colitis. The latest patent provides intellectual property rights in validated European countries through
Lucentis is a vascular endothelial growth factor (VEGF) inhibitor, designed to bind to and inhibit VEGF-A, a protein that is believed to play a major role in the
The EMA submission includes the registration of a new 25mg Powder for Oral Suspension formulation for eltrombopag and also a new 12.5mg tablet. The drug is indicated to
As part of the deal, Adimab will use its proprietary platform to produce therapeutic antibodies and bispecifics molecules against multiple targets, which will be developed and commercialized by
Velcade was approved for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone to treat MCL patients who are unsuitable for blood stem-cell transplantation. Currently, Velcade is indicated
Entrectinib is a new, orally available, selective tyrosine kinase inhibitor and is designed as a targeted therapeutic candidate to treat patients with cancers that harbor activating alterations to
As part of the deal, Hapten received a one-time upfront cash payment of $100,000 and 200,000 shares of RXi common stock. Hapten will also be eligible to receive
Nocdurna (desmopressin orally disintegrating tablets) is an antidiuretic that contains desmopressin, a structural analogue of the natural pituitary hormone arginine vasopressin. The drug works by stimulating vasopressin receptors
The data show that topical application of AKP-11 was safe, well-tolerated as well as resulted in a significant reduction in plaque severity. The company said that no detectable
Cytune is focused on researching and developing new therapies for immune modulation aimed to improve immune response of patients suffering from cancer and infectious diseases. PPF Group shareholder
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.